Key result
Mild hyperthermia safely increases LV AAV9 genome copies ~2.3-fold versus normothermia in preclinical models.
Why the study?
Low myocardial uptake of adeno-associated virus (AAV) is a major barrier for clinical translation of cardiac gene therapy, leading authors to test if mild hyperthermia enhances cardiac AAV9 gene delivery.
Does mild hyperthermia enhance cardiac AAV9 uptake and transgene expression in rodents, and is it safe in a porcine heart failure model?
Does mild hyperthermia enhance cardiac AAV9 uptake and transgene expression in rodents, and is it safe in a porcine heart failure model?
Controlled mild hyperthermia safely and selectively enhances cardiac AAV9 uptake and transgene expression in preclinical models, offering a promising strategy to improve the efficacy of cardiac gene therapy.
Answers are grounded in this paper and cite their sources.
May enhance cardiac AAV9 delivery in preclinical models; leaves open clinical translation and safety.
Low myocardial uptake of adeno-associated virus (AAV) is a major barrier for clinical translation of cardiac gene therapy. Because temperature modifies membrane dynamics, receptor availability, and viral entry, we hypothesized that mild hyperthermia could enhance cardiac AAV9 gene delivery. Rats (n=7/group) were maintained at core temperatures of 32°C, 37°C, or 40°C for 30 minutes during and after intravenous injection of AAV9.luciferase. Hearts and livers were harvested 4 weeks later to quantify vector genomes and transgene expression. Hyperthermia at 40°C increased left ventricular (LV) AAV9 genome copies by ~2.3-fold relative to both 37°C and 32°C (ANOVA p< 0.001; Tukey p< 0.001 vs both). It also significantly increased LV transgene expression by ~3.7-fold versus 32°C, and ~3.9-fold versus 37°C (ANOVA p=0.011; Tukey p< 0.05 vs both), whereas liver AAV9 uptake did not differ among the groups (ANOVA p=0.41). Vector genomes and transgene expression in the LV were strongly correlated (r 2 =0.95), indicating that enhanced expression was attributable to increased AAV uptake. To determine whether vector temperature or the body temperature is responsible, a separate cohort received intramyocardial AAV9 at either room temperature (25°C) or at 42°C under normothermic conditions (n=3/group). Genome copies (Welch’s t-test p=0.60) and transgene expression (p=0.95) did not differ between the injectate temperature groups, implying that systemic body temperature, rather than vector temperature, regulates AAV uptake. Immunofluorescent staining of LV sections (n=3–4/group) showed a non-significant trend toward a higher cell-surface localization of the AAV9 receptor, AAVR, at 40°C compared with 32°C and 37°C (ANOVA p=0.21), suggesting enhanced AAV9 receptor interaction under hyperthermia. Translational feasibility and safety were evaluated in a porcine ischemic heart failure model (n=2, LV ejection fraction ≤40%). Core temperature was increased to 40°C for 30 minutes using combined surface and endovascular heating. Hyperthermia was well tolerated without arrhythmias or hemodynamic instability aside from the expected rise in heart rate. Cooling back to normothermia was quick and without complications, and both animals completed one week follow-up. Serum troponin, liver enzymes, creatinine, and coagulation profiles showed no evidence of irreversible cardiac, hepatic, or renal injury. Together, these rodent and large-animal data suggest that controlled mild hyperthermia safely and selectively enhances cardiac AAV9 uptake, supporting temperature modulation as a promising strategy to improve the efficacy of cardiac AAV gene therapy. Funding: This work was supported by NIH R01 HL139963 and HL173593 (KI). SAM was supported by the NIH T32HL007824-23. We would like to acknowledge the Gene Therapy Resource Program (GTRP) of the National Heart, Lung, and Blood Institute, National Institutes of Health for providing the gene vectors used in this study. We would also like to acknowledge the equipment funding from NIH on the animal cathlab C-arm (S10OD034330). This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied Heart failure (n=29). Mild hyperthermia (40°C) vs. Normothermia (37°C) and hypothermia (32°C) was evaluated on Left ventricular AAV9 genome copies (~2.3-fold increase, p=<0.001). Mild hyperthermia at 40°C increased left ventricular AAV9 genome copies by ~2.3-fold and transgene expression by ~3.9-fold compared to 37°C in rodents, and was safe in a porcine model.
Synapse has enriched 10 related papers. Consider them for comparative context: